Join industry thought leaders Chris Montalbano and Barry Sands for a free webinar on March 24, 2022 and discover the Innovation Roadmap™ for medical device development.
The Innovation Roadmap™ is a development approach designed to yield innovation and competitive differentiation while conforming with the FDA-QSR & ISO-13485.
A properly formatted Innovation Roadmap™ can change a medical device development team’s perception as related to realizing the FDA’s recommendations and prescriptions are structured to yield innovation not inhibit. This is a PARADIGM SHIFT we take a deep dive into within this free webinar while exploring the roadmap.
- Learn the 3-Step Innovation Roadmap™ for optimized medical device development including Discovery Research™, MVP R&D, and AGILE Commercialization under ISO-13485.
- Understand how regulatory controls can be leveraged in the development process to produce a device that is truly innovative.
- Learn how to utilize a development process which results in a device that will be reliable, safe, and effective for its users while infusing competitive differentiation.
- Learn the key engineering/design disciplines and tools deployed to achieve innovation success.
- Review of Case Studies that demonstrate implementation of these innovation principles yielding advanced medical devices.
Our live webinar will be recorded. If you are unable to attend, please register and we will follow-up with a recording of the program.
Meet the Speakers
CEO, MIDI Product Development Corp.
As Co‐founder and engineering leader of MIDI, Chris joined MIDI in 1988 and for over 30 years has been committed to developing medical devices for clientele with advanced engineering, possessing optimized user design and cost effectiveness. He copioneered the firm’s DevelopmentDNA™ quality process and systems approach/Methodology, implementing a comprehensive thorough philosophy involving the fusion of design tied to reliable engineering, cost effective manufacturing design and advanced HMI utilizing these disciplines in harmonious concert. This quality process conforms with the FDA‐QSR & ISO‐13485 requirements yielding commercializable solutions, facilitating designs which can achieve FDA 510k tied to innovation and competitive differentiation. Chris’ strong vision‐oriented leadership provides a high level of skilled engineering problem‐solving methodologies with sensitivity to innovation design. He is a recipient of numerous national design and engineering awards along with dozens of utility patents. Chris was formally educated in Mechanical Engineering at Rensselaer Polytechnic Institute; and later obtained a Master’s in Business Administration from Hofstra University.
President & Founder, RQMIS Inc.
Barry is a biomedical engineer (with a chemical engineering concentration) with MBA having 35 years experience in regulatory/clinical/quality affairs for medical device/biotech companies. Seven years experience as a Biomedical Engineer and Sr. Scientific Reviewer at FDA/CDRH/ODE and FDA’s Boston District. This government experience was followed with seventeen (17) years in midlevel and executive management positions in small start-up and large multinational medical device companies. Market responsibilities included United States (including Puerto Rico), European Union, South America, Canada, Japan and South Korea. For the past 12 years, he has been leading RQMIS in assisting their clients in gaining market clearance in the US/EU/Canada/Brazil/etc. for their combination products (device/drug), medical devices, in-vitro diagnostics and dietary supplements.
Experience includes regulatory submissions (510k, IDE, PMA, HUD/HDE, Design Dossiers), Clinical Study Design/Management, Risk Management, Quality System Design/Audits (FDA QSR and ISO 13485) and FDA Negotiation and Communication (QSR Audits, 483s, Warning Letters, Bioresearch Monitoring, Medical Device Reports, Recalls).
Hear From Us
Sign up to receive emails highlighting our upcoming events, early registration savings, and engagement opportunities for the medical technology community.